Relafen 750, pharmacologically known as naproxen, represents a significant case study from a pharmaceutical pharmacy standpoint. The drug exhibits its therapeutic effect primarily by blocking the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby suppressing prostaglandin synthesis . The targeted inhibition of COX-2, compared to